Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia

Neuroscience

Volumn 248, Issue , 2013, Pages 252-260

  Zugno, A I ^a   de Miranda, I M ^a   Budni, J ^a   Volpato, A M ^a   Luca, R D ^a   Deroza, P F ^a   de Oliveira, M B ^a   Heylmann, A S ^a   da Rosa Silveira, F ^a   Wessler, P ^a   Antunes Mastella, G ^a   Cipriano, A L ^a   Quevedo, J ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Acetylcholinesterase; Ketamine; Locomotor activity; Maternal deprivation; Memory; Schizophrenia

Indexed keywords

ACETYLCHOLINESTERASE; KETAMINE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR CHANGE; CHEMICAL ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; ENZYME LOCALIZATION; HIPPOCAMPUS; INTEGRATION; LATENT PERIOD; LOCOMOTION; MALE; MATERNAL DEPRIVATION; NONHUMAN; PERINATAL PERIOD; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; RISK FACTOR; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; TASK PERFORMANCE; AGING; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; MEMORY; METABOLISM; MOTOR ACTIVITY; PSYCHOLOGY;

ACETYLCHOLINESTERASE; AGING; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; KETAMINE; LOCOMOTION; MALE; MATERNAL DEPRIVATION; MEMORY; MOTOR ACTIVITY; RATS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 84880363064     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.05.059     Document Type: Article

References (76)

1. Abi-Dargham A., Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005, 20:15-27.
2. Agid O., Shapira B., Zislin J., Ritsner M., Hanin B., Murad H., Troudart T., Bloch M., Heresco-Levy U., Lerer B. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol Psychiatry 1999, 2:163-172.
3. Aguilar M.C., Gurpegui M., Dias F., De Leon J. Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. Br J Psychiatry 2005, 186:215-221.
4. Angrist B., Sathananthan G., Wilk S. Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatry Res 1974, 11:13-23.
5. Barros D.M., Ramirez M.R., Izquierdo I. Modulation of working, short- and long-term memory by nicotinic receptors in the basolateral amygdala in rats. Neurobiol Learn Mem 2005, 83:113-118.
6. Becker A., Peters B., Shroeder H., Mann T., Huether G., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:687-700.
7. Bencherif M., Stachowiak M.K., Kucinski A.J., Lippiello P.M. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia. Med Hypotheses 2012, 78:594-600.
8. Benetti F., Mello P.B., Bonini J.S., Monteiro S., Cammarota M., Izquierdo I. Early postnatal maternal deprivation in rats induces memory deficits in adult life that can be reversed by donepezil and galantamine. Int J Dev Neurosci 2009, 27:59-64.
9. Berry K., Barrowclough C., Wearden A. A review of the role of adult attachment style in psychosis: unexplored issues and questions for further research. Clin Psychol Rev 2007, 27:458-475.
10. Bevilaqua L.R., Kerr D.S., Medina J.H., Izquierdo I., Cammarota M. Inhibition of hippocampal Jun N-terminal kinase enhances short term memory but blocks long-term memory formation and retrieval of an inhibitory avoidance task. Eur J Neurosci 2003, 17:897-902.
11. Bickel S., Javitt D.C. Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res 2009, 204:352-362.
12. Borlongan C.V., Sumaya I.C., Moss D.E. Methanesulfonyl fluoride, an acetylcholinesterase inhibitor, attenuates simple learning and memory deficits in ischemic rats. Brain Res 2005, 1038:50-58.
13. Bowlby J. Attachment and loss: vol. 2. Separation: anxiety and anger 1973, Basic Books, New York.
14. Bowlby J. A secure base: parent-child attachment and healthy human development 1988, Basic Books, New York.
15. Bradford A. The dopamine and glutamate theories of schizophrenia: a short review. Curr Anaesth Crit Care 2009, 20:240-241.
16. Brown R.W., Beale K.S., Jay Frye G.D. Mecamylamine blocks enhancement of reference memory but not working memory produced by post-training injection of nicotine in rats tested on the radial arm maze. Behav Brain Res 2002, 134:259-265.
17. Bubeníková-Valesová V., Horácek J., Vrajová M., Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav 2010, 32:1014-1023.
18. Canever L., Oliveira L., D'Altoé de Luca R., Correa P.T., de B Fraga D., Matos M.P., Scaini G., Quevedo J., Streck E.L., Zugno A.I. A rodent model of schizophrenia reveals increase in creatine kinase activity with associated behavior changes. Oxid Med Cell Longev 2010, 36:421-427.
19. Cannon M., Murray R.M. Neonatal origins of schizophrenia. Arch Dis Child 1998, 78:1-3.
20. Cardno A.G., Marshall E.J., Coid B., Macdonald A.M., Ribchester T.R., Davies N.J., Venturi P., Jones L.A., Lewis S.W., Sham P.C., Gottesman I.I., Farmer A.E., McGuffin P., Reveley A.M., Murray R.M. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999, 56:162-168.
21. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharm Toxicol 1963, 20:140-144.
22. Chatterjee M., Verma R., Ganguly S., Palit G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology 2012, 63:1161-1171.
23. Day T., Greenfield S.A. A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: molecular mechanisms. Neuroscience 2002, 111:649-656.
24. De Oliveira L., Fraga D.B., De Luca R.D., Canever L., Ghedim F.V., Matos M.P., Streck E.L., Quevedo J., Zugno A.I. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metab Brain Dis 2011, 26:69-77.
25. Dingledine R., Boges K., Bowie D., Travnelis S.F. The glutamate receptor ion channels. Pharmacol Rev 1999, 51:7-51.
26. Drusch K., Lowe A., Fisahn K., Brinkmeyer J., Musso F., Mobascher A., Warbrick T., Shah J., Ohmann C., Winterer G., Wölwer W. Effects of nicotine on social cognition, social competence and self-reported stress in schizophrenia patients and healthy controls. Eur Arch Psychiatry Clin Neurosci 2012, 1-9.
27. Ellman G.L., Courtney K.D., Andres J.R., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
28. Emmett S.R., Greenfield S.A. A peptide derived from the C-terminal region of acetylcholinesterase modulates extracellular concentrations of acetylcholinesterase in the rat substantia nigra. Neurosci Lett 2004, 358:210-214.
29. Erlenmeyer-Kimling L., Rock D., Squires-Wheeler E., Roberts S., Yang J. Early life precursors of psychiatric outcomes in adulthood in subjects at risk for schizophrenia or affective disorders. Psychiatry Res 1991, 39:239-256.
30. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 2003, 1003:119-130.
31. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull 2008, 36:359-369.
32. Gama C.S., Canever L., Panizzutti B., Gubert C., Stertz L., Massuda R., Pedrini M., de Lucena D.F., Luca R.D., Fraga D.B., Heylmann A.S., Deroza P.F., Zugno A.I. Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr Res 2012, 141:162-167.
33. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Andreazza A.C., Stertz L., Fries G.R., Gavioli E.C., Kapczinski F., Quevedo J. Chronic administration of ketamine elicits antidepressant-like effects in rats without Affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 2008, 103(6):502-506.
34. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Stertz L., Kapczinski F., Gavioli E.C., Quevedo J. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:450-455.
35. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004, 50:433-440.
36. Gold P.E. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 2003, 80:194-210.
37. Harvey C.R., Curson D.A., Pantelis C. Four behavioural syndromes of schizophrenia. Br J Psychiatry 1996, 168:562-570.
38. Hunt M.J., Raynaud B., Garcia R. Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens in freely moving rats. Biol Psychiatry 2006, 60:1206-1214.
39. Imre G., Fokkema D.S., Den Boer J.A., Ter Horst G.J. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 2006, 69:338-345.
40. Izquierdo I., Barros D.M., Mello e Souza T., De Souza M.M., Izquierdo L.A., Medina J.H. Mechanisms for memory types differ. Nature 1998, 393:635-636.
41. Jones P., Rodgers B., Murray R., Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994, 344:1398-1402.
42. Karam C.S., Ballon J.S., Bivens N.M., Freyberg Z., Girgis R.R., Lizardi-Ortiz J.E., Markx S., Lieberman J.A., Javitch J.A. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 2010, 31(8):381-390.
43. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndromescale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
44. Kéri S., Szamosi A., Benedek G., Kelemen O. How does the hippocampal formation mediate memory for stimuli processed by the magnocellular and parvocellular visual pathways? Evidence from the comparison of schizophrenia and amnestic mild cognitive impairment (aMCI). Neuropsychologia 2012, 50:3193-3199.
45. Kim J.S., Kprmkiber W., Schimid-Burgk B., Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20:379-382.
46. Lambás-Señas L., Mnie-Filali O., Certin V., Faure C., Lemoine L., Zimmer L., Haddjeri N. Functional correlates for 5-HT(1A) receptors in maternally deprived rats displaying anxiety and depression-like behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:262-268.
47. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002, 25:409-432.
48. Lherena A., De La Rubia A., Peñas-Lledó E.M. Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophr Res 2003, 60:313-317.
49. Lima M.N., Laranja D.C., Bromberg E., Roesler R., Schröder N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 2005, 156:139-143.
50. Lipska B.K., Weinberber D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
51. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-267.
52. Marek G., Merchant K. Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRx 2005, 2:579-589.
53. Mccreadile R.G. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. J Psychiatry 2002, 181:321-325. On behalf of the Scottish Comorbidity Study Group.
54. Moghaddam B., Jackson M. Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 2003, 1003:131-137.
55. Morgan C.J., Mofeez B.B., Bromley L., Curran H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004, 29:208-218.
56. Newcomer J.W. Ketamine-induced NMDA receptor hyperfunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
57. Niesink R.J.M., Van Ree J.M. Involvement of opioid and dopaminergic systems in isolation-induced pinning and social grooming of young rats. Neuropharmacology 1989, 28:411-418.
58. Nikiforuk A., Gołembiowska K., Popik P. Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 2010, 20:37-48.
59. Oda Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 1999, 49:921-937.
60. Park S., Holzman P.S. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992, 49:975-982.
61. Prado V.F., Martins-Silva C., de Castro B.M., Lima R.F., Barros D.M., Amaral E., Ramsey A.J., Sotnikova T.D., Ramirez M.R., Kim H.G., Rossato J.I., Koenen J., Quan H., Cota V.R., Moraes M.F., Gomez M.V., Guatimosim C., Wetsel W.C., Kushmerick C., Pereira G.S., Gainetdinov R.R., Izquierdo I., Caron M.G., Prado M.A. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron 2006, 51:601-612.
62. Quevedo J., Moretto A., Colvero M., Roesler R., Ferreira M.B. The N-methyl-d-aspartate receptor blocker MK-801 prevents the facilitatory effects of naloxone and epinephrine on retention of inhibitory avoidance task in rats. Behav Pharmacol 1997, 8:471-474.
63. Read J., Perry B.D., Moskowitz A., Connolly J. The contribution of early traumatic events to schizophrenia in some patients: a traumagenic neurodevelopmental model. Psychiatry 2001, 64:319-345.
64. Réus G.Z., Stringari R.B., Ribeiro K.F., Ferraro A.K., Vitto M.F., Cesconetto P., Souza C.T., Quevedo J. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 2011, 221:166-171.
65. Roesler R., Schröder N., Vianna M.R., Quevedo J., Bromberg E., Kapczinski F., Ferreira M.B. Differential involvement of hippocampal and amygdalar NMDA receptors in contextual and aversive aspects of inhibitory avoidance memory in rats. Brain Res 2003, 975:207-213.
66. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 1997, 8:196-215.
67. Sams-Dodd F. Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
68. Schneider T., Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
69. Schultz S.H., North S.W., Shields C.G. Schizophrenia: a review. Am Fam Physician 2007, 75:1821-1829.
70. Smith J.W., Gastambide F., Gilmour G. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology 2011, 217:255-269.
71. Slotkin T.A., Ryde I.T., Wrench N., Card J.A., Seidler F.J. Nonenzymatic role of acetylcholinesterase in neuritic sprouting: regional changes in acetylcholinesterase and choline acetyltransferase after neonatal 6-hydroxydopamine lesions. Neurotoxicol Teratol 2009, 31:183-186.
72. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994, 51:139-154.
73. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000, 57:1139-1147.
74. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
75. Wicks S., Hjern A., Gunnell D., Lewis G., Dalman C. Social adversity in childhood and the risk of developing psychosis: a national cohort study. Am J Psychiatry 2005, 162:1652-1657.
76. Zierhut K.C., Schulte-Kemna A., Kaufmann J., Steiner J., Bogerts B., Schiltz K. Distinct structural alterations independently contributing to working memory deficits and symptomatology in paranoid schizophrenia. Cortex 2012, 49(4):1063-1072.